VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
XRAY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
XRAYDENTSPLY SIRONA Inc.
$12.19$2.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksXRAYCash Flow

DENTSPLY SIRONA Inc. (XRAY) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow has turned negative to -$12 million in 2026Q1, reflecting a significant disconnect between accounting results and cash-generating capacity.

XRAY Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations268M235M461M377M517M657M649M632.8M499.8M601.9M563.4M497.4M560.4M417.85M369.69M393.47M362.32M362.49M335.98M387.7M271.86M232.77M306.26M257.99M172.98M211.07M145.62M121.3M93.7M94.3M83.2M
Operating CF Margin %-6.39%12.15%9.51%13.18%15.53%19.44%15.73%12.54%15.07%15.04%18.6%19.17%14.16%12.62%15.5%16.31%16.78%15.32%19.29%15.02%13.57%18.08%16.42%11.43%18.69%16.37%14.6%11.78%13.08%12.67%
Operating CF Growth %366.63%-49.02%22.28%-27.08%-21.31%1.23%2.56%26.61%-16.96%6.83%13.27%-11.24%34.12%13.03%-6.04%8.6%-0.05%7.89%-13.34%42.61%16.79%-24%18.71%49.14%-18.04%44.94%20.05%29.46%-0.64%13.34%23.26%
Net Income-628M-598M-910M-132M-950M411M-73M263.1M-1.01B-1.57B431.4M251.1M322.91M318.16M318.49M247.45M267.33M274.41M283.87M259.65M223.72M45.41M210.29M169.85M147.95M121.5M101.02M89.9M34.8M74.6M67.2M
Depreciation & Amortization353M352M349M343M328M346M334M322.8M330.8M316.4M271.7M122.9M129.08M127.9M129.2M85.03M66.34M65.17M56.93M50.29M47.43M50.56M49.3M45.66M43.86M54.33M41.36M39.6M37.5M32.4M28.1M
Stock-Based Compensation16M33M39M46M59M48M47M66.2M21M48M41.3M25.6M25.43M25.1M22.19M20.95M18.8M16.28M17.29M14.09M19.62M0000000000
Deferred Taxes-31M30M-136M-130M-228M-25M-62M-37.4M-62M-143.8M-110.1M15.8M15.39M-31.56M-78.54M-88.4M1.39M195K13.37M25.57M53.7M-91.78M7.06M32.41M-6.02M6.45M4.25M5.9M-22.1M-1.8M-3M
Other Non-Cash Items668M640M1.02B339M1.39B3M203M50M1.26B2.08B-15M43.9M21.2M38.5M15.79M29.64M-5.33M-13.78M-6.97M-21.16M21.3M233.23M-57.99M5.83M9.77M-20.32M2.76M2.13M72.61M800K700K
Working Capital Changes-111M-222M95M-89M-78M-126M200M-19.8M-33.2M-144.8M-43.2M38.1M46.48M-60.22M-38.55M95.99M5.38M20.21M-28.51M46.75M-74.29M-3.67M55.82M4.24M-22.58M49.11M-3.76M-14.6M-27.5M-11.7M-9.8M
Change in Receivables0-91M104M-58M85M-117M131M-91.4M23.5M-63.4M-75.1M-900K7.2M-32.53M-12.59M1.47M5.12M-3.74M-3.69M9.03M-19.98M0000000000
Change in Inventory-14M-17M17M6M-141M-64M123M13.7M-19.9M-62.9M65.4M32.1M21.03M-25.37M-36.79M21.5M-9.31M27.71M-32.82M-716K-10.78M-7.46M4.1M15.2M-8.94M14.76M-1.22M4.4M-5.6M1.7M300K
Change in Payables-1M11M-30M14M30M-49M-28M26.1M7.1M44.2M7.2M8.8M10.04M-36.73M12.84M10.82M2.17M-4.95M5.43M-7.39M-6.58M0000000000
Cash from Investing-168M-132M-197M-89M-138M-358M-1.11B-68.4M-253.3M-286.4M60M-54.9M138.69M260.23M-115.02M-1.89B-129.49M-53.4M-47.8M-299.39M-76.29M-42.47M25.61M-69.38M-84.5M-814.69M-44.63M-35.5M-142.4M-111.2M-98.7M
Capital Expenditures-164M-131M-180M-149M-149M-142M-87M-122.9M-188M-151M-126.1M-72M-105.77M-101.42M-95.4M-74.25M-45.84M-56.49M-78.92M-65.83M-52.61M-45.29M-56.26M-78.99M-57.45M-49.34M-28.43M-36.7M-139.9M-108.9M-23.8M
CapEx % of Revenue4.46%3.56%4.75%3.76%3.8%3.36%2.61%3.06%4.72%3.78%3.37%2.69%3.62%3.44%3.26%2.93%2.06%2.62%3.6%3.28%2.91%2.64%3.32%5.03%3.8%4.37%3.19%4.42%17.6%15.11%3.62%
Acquisitions-1M0013M0-220M-1.08B8.4M-130.5M-145.9M-335.7M-54M-2.04M-66.25M-4.86M-1.79B-35.56M-2.99M-117.3M-101.49M-32.08M-18.1M-17.16M-15.04M-49.8M-812.52M-14.99M0000
Investments-------------------------------
Other Investing-4M-1M-17M47M-2M2M1M-117M-179.3M-144.5M399.5M-105.8M-106.1M-99.9M-95.94M-89.84M-93.93M-50.63M-78.32M6.33M8.18M24.39M13.55M6.05M22.76M47.17M-1.21M-1.43M-4.13M-2.3M-74.9M
Cash from Financing-322M-80M-302M-307M-329M-379M476M-466.1M-249.8M-400.8M-526.2M-302.9M336.18M161.69M-255.61M1B-101.4M-71.42M-229.09M3.24M-612.57M-212.37M-16.07M-60.77M-99.37M624.9M-99.11M-83M51.4M23.7M19.3M
Debt Issued (Net)-107M54M90M119M-60M-102M749M-200.8M51M-3.4M299M-116.8M-84.9M-19.5M-228.91M1.12B116.82M20.22M-106.14M96.79M-362.01M-60.25M-21.53M-73.38M-94.01M623.5M-53.44M-73.63M98.15M27.2M29.1M
Equity Issued (Net)00-250M-300M-150M-200M-228M-260M-250M-401.4M-813.9M-112.7M-163.2M-118M-38.84M-79.5M-223.99M-78.72M-112.63M-125.42M-240.16M-132.98M7.62M16.87M9.05M7.14M-32.67M285K-38.23M6.8M-2.3M
Dividends Paid-128M-128M-126M-116M-104M-92M-88M-80.9M-78.6M-78.3M-64.6M-40M-37.39M-34.87M-31.43M-28.63M-29.08M-29.84M-26.95M-25.13M-21.86M-19.14M-15.82M-15M-14.36M-14.23M-13M-11.9M-11M-10.2M-8.9M
Share Repurchases00-250M-300M-150M-200M-228M-260M-250M-401.4M-813.9M-112.7M-163.2M-118M-38.84M-79.5M-223.99M-78.72M-112.63M-125.42M-293.77M-164.76M-37.7M00-875K-40.09M-3.89M-42.05M-900K-3.8M
Other Financing-87M-6M-16M-10M-15M15M43M75.6M27.8M82.3M53.3M-33.4M-50.66M10.67M43.56M-14.28M34.85M16.91M16.64M57.01M11.46M013.66M0-53K8.49M0046K-100K1.4M
Net Change in Cash-208M54M-62M-31M26M-99M33M95.3M-11M-63.3M99.3M133M76.69M-5.18M3M-462.91M89.69M246.36M34.61M104.32M-368.92M-71.84M342.61M138.1M-8.06M18.28M4.01M-1.4M-1.2M4.2M1.7M
Free Cash Flow104M104M281M228M368M515M562M509.9M311.8M450.9M437.3M425.4M454.63M316.43M274.28M319.21M316.48M305.99M257.06M321.87M219.24M187.48M250M179M115.53M161.73M117.2M84.6M-46.2M-14.6M59.4M
FCF Margin %2.83%2.83%7.41%5.75%9.38%12.17%16.83%12.68%7.82%11.29%11.68%15.91%15.56%10.72%9.37%12.58%14.25%14.17%11.72%16.01%12.11%10.93%14.76%11.39%7.63%14.32%13.17%10.18%-5.81%-2.03%9.05%
FCF Growth %-62.59%-62.99%23.25%-38.04%-28.54%-8.36%10.22%63.53%-30.85%3.11%2.8%-6.43%43.68%15.36%-14.08%0.86%3.43%19.03%-20.13%46.81%16.94%-25.01%39.67%54.94%-28.57%38%38.53%283.12%-216.44%-124.58%19.04%
FCF per Share0.520.521.381.081.712.342.562.271.391.971.972.993.152.181.912.222.172.041.692.081.391.161.521.110.721.020.750.53-0.29-0.090.37
FCF Conversion (FCF/Net Income)-0.17x-0.39x-0.51x-2.86x-0.54x1.60x-8.89x2.47x-0.49x-0.39x1.31x1.98x1.74x1.33x1.18x1.61x1.36x1.32x1.18x1.49x1.22x5.13x1.21x1.48x1.17x1.74x1.44x1.35x2.69x1.26x1.24x
Interest Paid0091M97M70M64M45M30M35M37M36.7M54.9M47.8M50.5M60.17M34.05M21.86M23.23M34.22M21.93M00000000000
Taxes Paid0074M177M122M148M82M112M105M122.7M112.3M-71.4M-48.7M49.8M109.54M58.65M64.79M76.21M66.7M38.09M00000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowDeteriorating
Top Statement Risk

Persistent Cash Flow Volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Remains Severely Disconnected

According to recent financial disclosures, XRAY's operating cash flow to net income ratio has frequently turned negative, with the 2026Q1 figure of -4.00 highlighting a profound disconnect between reported accounting losses and the actual cash-generating capacity of the underlying dental equipment and consumables business model.

The persistent divergence between net income and operating cash flow suggests that non-cash charges, likely related to restructuring and asset impairments, are masking the true operational cash profile. Investors should monitor whether this gap narrows as the company attempts to stabilize its cost structure, as current figures imply that accounting earnings are not a reliable proxy for cash liquidity.

Free Cash Flow Trajectory Remains Erratic

As reported in quarterly filings, XRAY's free cash flow has exhibited extreme volatility, swinging from a peak of $156 million in 2024Q2 to a deficit of $12 million in 2026Q1, indicating that the company struggles to maintain consistent cash generation amidst its ongoing operational restructuring efforts.

The inability to sustain positive free cash flow suggests that the company's capital-intensive business model is highly sensitive to cyclical demand shifts and internal integration costs. This inconsistency warrants further investigation into whether the current cash burn is a temporary byproduct of strategic realignment or a sign of structural margin degradation.

Capital Intensity Pressures Cash Reserves

Based on the provided data, XRAY's capital expenditure as a percentage of revenue reached 5.9% in 2026Q1, reflecting a sustained commitment to maintaining its manufacturing footprint despite the company's broader struggle to achieve consistent profitability across its core dental technology and equipment segments.

High capital intensity relative to revenue suggests that the company must continue to invest heavily in its specialized manufacturing and R&D to defend its market position. If these investments do not yield a corresponding improvement in operating margins, the company may face increasing pressure on its liquidity profile.

Working Capital Swings Obscure Efficiency

Data from recent financial statements reveals significant fluctuations in working capital, including a $113 million outflow in 2025Q2, which suggests that the company's cash conversion cycle remains highly sensitive to inventory management and the timing of collections within its global dental distribution network.

These erratic working capital movements imply that the company may be struggling to optimize its supply chain or manage customer payment terms effectively during periods of market volatility. Investors should monitor these trends closely, as they may indicate underlying inefficiencies in how the company manages its inventory of high-ticket dental hardware.

XRAY — Frequently Asked Questions

Quick answers to the most common questions about buying XRAY stock.

How much cash does DENTSPLY SIRONA Inc. (XRAY) generate from operations?

DENTSPLY SIRONA Inc. (XRAY) generated $235.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is DENTSPLY SIRONA Inc.'s free cash flow?

DENTSPLY SIRONA Inc. (XRAY) generated $104.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is DENTSPLY SIRONA Inc.'s capital expenditure (CapEx)?

DENTSPLY SIRONA Inc. (XRAY) spent $131.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does DENTSPLY SIRONA Inc. distribute cash to shareholders?

In 2025, DENTSPLY SIRONA Inc. (XRAY) returned $128.0M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.